Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TY-4028
- Development stage
- Unknown
- Lead developer
- Zhejiang Tongyuan Kang Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TY-4028 is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) developed by Zhejiang Tongyuan Kang Medicine (also known as TYK Medicines). It is specifically designed to target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) harboring exon 20 insertion mutations. These specific genetic alterations are typically resistant to first- and second-generation TKIs due to structural changes in the kinase domain that limit the therapeutic window between mutant and wild-type receptors. TY-4028 aims to selectively inhibit these mutants, thereby blocking downstream signaling pathways such as PI3K/AKT and MAPK/ERK that drive tumor cell proliferation and survival. The compound is currently undergoing Phase 1/2 clinical evaluation to determine its safety, tolerability, and preliminary efficacy in patients with advanced non-small cell lung cancer (NSCLC).
- Other names
- TY-4028TY4028TY 4028
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TY-4028.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TY-4028.